Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus

World Journal of Gastroenterology

Volumn 14, Issue 29, 2008, Pages 4697-4700

  Okan, Gokhan ^a   Yaylaci, Serpil ^a   Peker, Onder ^a   Kaymakoglu, Sabahattin ^b   Saruc, Murat ^a  

^a Acibadem Bakirkoy Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ciprofloxacin; Stevens Johnson syndrome; Tacrolimus; Vanishing bile duct syndrome

Indexed keywords

CIPROFLOXACIN; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BILE DUCT DISEASE; BRONCHITIS; CASE REPORT; CHOLESTASIS; CLINICAL EXAMINATION; CUSHING SYNDROME; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSURIA; ECHOGRAPHY; FEMALE; FEVER; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEDICAL LITERATURE; RASH; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME; VANISHING BILE DUCT SYNDROME; CHEMICALLY INDUCED DISORDER;

ADULT; BILE DUCT DISEASES; CIPROFLOXACIN; DEGLUTITION DISORDERS; DYSURIA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STEVENS-JOHNSON SYNDROME; TACROLIMUS; TREATMENT OUTCOME;

EID: 58149186739     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4697     Document Type: Article

References (16)

1. Morelli MS, O'Brien FX. Stevens-Johnson Syndrome and cholestatic hepatitis. Dig Dis Sci 2001; 46: 2385-2388
2. Cac NN, Messingham MJ, Sniezek PJ, Walling HW. Stevens-Johnson syndrome induced by doxycycline. Cutis 2007; 79: 119-122
3. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44
4. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607
5. Srivastava M, Perez-Atayde A, Jonas MM. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 1998; 115: 743-746
6. Hallgren J, Tengvall-Linder M, Persson M, Wahlgren CF. Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol 2003; 49: S267-S269
7. Garcia M, Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD. Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes. Dig Dis Sci 2002; 47: 177-182
8. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992; 33: 183-186
9. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-531
10. Jakab SS, West AB, Meighan DM, Brown RS Jr, Hale WB. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol 2007; 13: 6087-6089
11. Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, Marzano A, Quaglino P, De Simone C, Parodi A, Barletta E, Fabbri P. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155: 722-728
12. Chia FL, Leong KP. Severe cutaneous adverse reactions to drugs. Curr Opin Allergy Clin Immunol 2007; 7: 304-309
13. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008; 358: 637-639
14. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 317-323
15. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-1018
16. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579